Векторы в генотерапии рака: преимущество спор клостридий перед вирусами (продолжение...)

24. Wang XY, Martiniello-Wilks R, Shaw JM, Ho T, Coulston N, Cooke-Yarborough C, Molloy PL, Cameron F, Moghaddam M, Lockett TJ, Webster LK, Smith IK, Both GW, Russell PJ: Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus. Gene Ther 2004, 11(21):1559-67.

25. Matthews QL, Sibley DA, Wu H, Li J, Stoff-Khalili MA, Waehler R, Mathis JM, Curiel DT: Genetic incorporation of a herpes simplex virus type 1 thymidine kinase and firefly luciferase fusion into the adenovirus protein IX for functional display on the virion. Mol Imaging 2006, 5(4):510-9.

26. Flotte TR: Gene Therapy Progress and Prospects: Recombinant adeno-associated virus (rAAV) vectors. Gene Ther 2004, 11(10):805-10.

27. Urabe M, Nakakura T, Xin KQ, Obara Y, Mizukami H, Kume A, Kotin RM, Ozawa K: Scalable generation of high-titer recombinant adeno-associated virus type 5 in insect cells. J Virol 2006, 80(4):1874-85.

28. Harland J, Dunn P, Cameron E, Conner J, Brown SM: The herpes simplex virus (HSV) protein ICP34.5 is a virion component that forms a DNA-binding complex with proliferating cell nuclear antigen and HSV replication proteins. J Neurovirol 2003, 9(4):477-88.

29. Derubertis BG, Stiles BM, Bhargava A, Gusani NJ, Hezel M, D'Angelica M, Fong Y: Cytokine-secreting herpes viral mutants effectively treat tumor in a murine metastatic colorectal liver model by oncolytic and T-cell-dependent mechanisms. Cancer Gene Ther 2007 in press.

30. Lee JS, Lee JH, Poo H, Kim MS, Lee SH, Sung MH, Kim CJ: Growth inhibitory effect of triple anti-tumor gene transfer using Semliki Forest virus vector in glioblastoma cells. Int J Oncol 2006, 28(3):649-54.

31. Izsvak Z, Ivics Z, Plasterk RH: Sleeping beauty, a wide host-range transposon vector for genetic transformation in vertebrates. J Mol Biol 2000, 302:93-102.

32. Zhu ZB, Makhija SK, Lu B, Wang M, Rivera AA, Preuss M: Transport across a polarized monolayer of Caco-2 cells by transferring receptor-mediated adenovirus transcytosis. Virology 2004, 325:116-128.

33. McIntosh DP, Tan XY, Oh P, Schnitzer JE: Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery. Proc Natl Acad Sci USA 2002, 99:1996-2001.

34. Li J, Le LP, Sibley DA, Mathis JM, Curiel DT: Genetic incorporation of HSV-1 thymidine kinase into the adenovirus protein ix for functioal display on the virion. Virology 2005, 338:247-258.

35. Pankhurst QA, Connolly J, Jones SK, Dobson J: Applications of magnetic nanoparticles in biomedicine. J Phys D Appl Phys 2003, 36:R167-R181.

36. Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA, Roth JA: Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 1994, 86:1458-1462.

37. Zhang WW, Fang X, Mazur W, French BA, Georges RN, Roth JA: High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1994, 1:5-13.

38. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, Pisters KM, Putnam JB, Schea R, Shin DM, Walsh GL, Dolormente MM, Han CI, Martin FD, Yen N, Xu K, Stephens LC, McDonnell TJ, Mukhopadhyay T, Cai D: Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996, 2:985-991.

39. Schuler M, Rochlitz C, Horowitz JA, Schlegel J, Perruchoud AP, Kommoss F, Bolliger CT, Kauczor HU, Dalquen P, Fritz MA, Swanson S, Herrmann R, Huber C: A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced nonsmall cell lung cancer. Hum Gene Ther 1998, 9(14):2075-2082.

40. Gahery-Segard H, Molinier-Frenkel V, Le Boulaire C, Saulnier P, Opolon P, Lengagne R, Gautier E, Le Cesne A, Zitvogel L, Venet A, Schatz C, Courtney M, Le Chevalier T, Tursz T, Guillet JG, Farace F: Phase 1 trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. J Clin Invest 1997, 100:2218-2226.

41. Nemunaitis J, Swisher SG, Timmons T, Connors D, Mack M, Doerksen L, Weill D, Wait J, Lawrence DD, Kemp BL, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB, Richli WR, Shin DM, Walsh GL, Merritt J, Roth J: Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-smallcell lung cancer. J Clin Oncol 2000, 18:609-622.

42. Hwang HC, Smythe WR, Elshami AA, Kucharczuk JC, Amin KM, Williams JP, Litzky LA, Kaiser LR, Albelda SM: Gene therapy using adenovirus carrying the herpes simplex thymidine kinase gene to treat in vitro models of human malignant mesothelioma and lung cancer. Am J Respir Cell Mol Biol 1995, 13:7-16.

43. Sterman DH, Treat J, Litzky LA, Amin KM, Coonrod L, Molnar-Kimber K, Recio A, Knox L, Wilson JM, Albelda SM, Kaiser LR: Adenovirus-mediated herpes simplex virus thymidine kinase gene delivery in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998, 9:1083-1092.

44. Liu CS, Kong BH, Xia HQ, Ellem KA, Wei MQ: VP22 enhanced intercellular trafficking of HSV thymidine kinase reduced the level of ganciclovir needed to cause suicide cell death. J Gene Med 2001, 3:145-152.

45. Schuler M, Herrmann R, De Greve JL, Stewart AK, Gatzemeier U, Stewart DJ, Laufman L, Gralla R, Kuball J, Buhl R, Heussel CP, Kommoss F, Perruchoud AP, Shepherd FA, Fritz MA, Horowitz JA, Huber C, Rochlitz C: Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced nonsmall cell lung cancer; results of a multicenter phase II study. J Clin Oncol 2001, 19:1750-1758.

46. Metharom P, Ellem K, Schmidt C, Wei MQ: Lentiviral vectormediated tyrosinase-related protein-2 gene transfer to dentritic cells for the therapy of melanoma. Human Gene Ther 2001, 12(18):2203-2213.

47. O'Reilly MS, Holmgren L, Chen C, Folkman J: Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med 1996, 2:689-692.

48. O'Reilly M: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.

49. Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP, Reisfeld RA: A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 2002, 8:1369-1375.

50. Zhang M, Zhang X, Bai CX, Chen J, Wei MQ: Inhibition of epidermal growth factor receptor (EGFR) by RNA interference in A549 cells. Acta Pharmacol Sin 2004, 25(1):61-7.

51. Parker RC, Plummber HC, Siebenmann CO, Chapman MG: Effect of hispolyticus infection and toxin on transplantable mouse tumours. Proc Soc Exp Biol Med 1947, 66:461-465.

52. Malmgren RA, Flanigan CC: Localization of the vegetative form of Clostridium tetani in mouse tumors following intravenous spore administration. Cancer Res 1955, 15(7):473-8.

53. Mцse JR, Mцse GZ: Onkolyseversuche mit apathogen, anaerogen sporenbildern am Erhlich-Tumor der maus. Z Krebsforsch 1959, 63:63-74.

54. Lemmon MJ, van Zijl P, Fox ME, Mauchline ML, Giaccia AJ, Minton NP, Brown JM: Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Ther 1997, 4:791-796.

55. Lambin P, Theys J, Landuyt W, Rijken P, van der Kogel A, van der Schueren E, Hodgkiss R, Fowler J, Nuyts S, de Bruijn E, Van Mellaert L, Annй J: Colonisation of Clostridium in the body is restricted to hypoxic and necrotic areas of tumours. Anaerobe 1998, 4:183-188.

56. Schlechte H, Elbe B: Recombinant plasmid DNA variation of Clostridium oncolyticum-model experiments of cancerostatic gene transfer. Zbl Bakt Hyg A 1988, 268(3):347-56.

57. Liu SC, Minton NP, Giaccia AJ, Brown JM: Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther 2002, 9(4):291-6.

58. Theys J, Landuyt AW, Nuyts S, Van Mellaert L, Lambin P, Annй J: Clostridium as a tumor-specific delivery system of therapeutic proteins. Cancer Detect Prev 2001, 25(6):548-57.

59. Van Mellaert L, Barbe S, Anne J: Clostridium spores as antitumour agents. Trends Microbiol 2006, 14(4):190-6.

60. Wei MQ, Mengesha A, Good D, Annй J: Bacterial targeted tumour therapy-dawn of a new era. Cancer Lett 259(1):16-27. 2008, Jan 1861. Theys J, Pennington O, Dubois L, Anlezark G, Vaughan T, Mengesha A, Landuyt W, Ann J, Burke PJ, Durre P, Wouters BG, Minton NP, Lambin P: Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo. Br J Cancer 2006, 95(9):1212-9.

62. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, Wilson JM, Batshaw ML: Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003, 80(1– 2):148-58.

63. Yang Y, Li Q, Ertl HC, Wilson JM: Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995, 69:2004-2015.






Наиболее просматриваемые статьи: